PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33937418-8	2021	Alanine scanning of epitope revealed that the peptide fragment 344RGDRWIQDEIEF355 was responsible for generating strong antibody responses that inhibit the PAD2-catalyzed citrullination reaction.	Alanine	0-7	MMTV LTR integration site 2	Mus musculus	156-160
29981294-4	2018	Here, we showed that treatment with YW3-56, a PAD2/PAD4 inhibitor, significantly diminished PAD activation, blocked LPS-induced pulmonary vascular leakage, alleviated acute lung injury, and improved survival in a mouse model of lethal LPS-induced endotoxemia.	YW3-56	36-42	MMTV LTR integration site 2	Mus musculus	46-50
28766045-3	2017	Here, PAD2OE mice were treated with the carcinogen, 9,10-dimethyl-1,2-benzanthracene and with O-tetradecanoylphorbol-13-acetate and then scored for papilloma formation.	9,10-Dimethyl-1,2-benzanthracene	52-84	MMTV LTR integration site 2	Mus musculus	6-10
29318161-7	2017	LPS, ATP, and TNF triggered PAD2 and PAD4 expression; in contrast, no expression was detected in the control group (p < 0.001).	Adenosine Triphosphate	5-8	MMTV LTR integration site 2	Mus musculus	28-32
28341402-4	2017	Further experiments suggested that compound 22, a non-covalent inhibitor of PAD2 and PAD4, exhibits dose-dependent efficacy in the EAE mouse model and in the cuprizone-mediated demyelination model.	Cuprizone	158-167	MMTV LTR integration site 2	Mus musculus	76-80
29318161-9	2017	Additionally, PAD2/4 activity modified the arginine residues of a reporter protein (fibrinogen) in vitro.	Arginine	43-51	MMTV LTR integration site 2	Mus musculus	14-18
27603413-7	2016	Once in the nucleus, GnRHa stimulated PAD2 citrullinates histone H3 tail arginine residues at sites 2, 8, and 17 within 30 minutes; however, this effect and PAD2 nuclear localization was blunted by incubation of the cells with the pan-PAD inhibitor, biphenyl-benzimidazole-Cl-amidine.	Arginine	73-81	MMTV LTR integration site 2	Mus musculus	38-42
27603413-7	2016	Once in the nucleus, GnRHa stimulated PAD2 citrullinates histone H3 tail arginine residues at sites 2, 8, and 17 within 30 minutes; however, this effect and PAD2 nuclear localization was blunted by incubation of the cells with the pan-PAD inhibitor, biphenyl-benzimidazole-Cl-amidine.	Arginine	73-81	MMTV LTR integration site 2	Mus musculus	157-161
27603413-7	2016	Once in the nucleus, GnRHa stimulated PAD2 citrullinates histone H3 tail arginine residues at sites 2, 8, and 17 within 30 minutes; however, this effect and PAD2 nuclear localization was blunted by incubation of the cells with the pan-PAD inhibitor, biphenyl-benzimidazole-Cl-amidine.	biphenyl-benzimidazole-cl-amidine	250-283	MMTV LTR integration site 2	Mus musculus	38-42
27603413-7	2016	Once in the nucleus, GnRHa stimulated PAD2 citrullinates histone H3 tail arginine residues at sites 2, 8, and 17 within 30 minutes; however, this effect and PAD2 nuclear localization was blunted by incubation of the cells with the pan-PAD inhibitor, biphenyl-benzimidazole-Cl-amidine.	biphenyl-benzimidazole-cl-amidine	250-283	MMTV LTR integration site 2	Mus musculus	157-161
34961522-4	2021	METHODS: Mouse cortical myelin isolated by ultracentrifugation was citrullinated ex vivo by incubation with the calcium-dependent peptidyl arginine deiminase PAD2.	Calcium	112-119	MMTV LTR integration site 2	Mus musculus	158-162
26315757-7	2015	Yueju or ketamine reversed these changes at PAD 2, but only Yueju reversed phosphor-Akt at PAD 6.	Ketamine	9-17	MMTV LTR integration site 2	Mus musculus	44-49
26315757-8	2015	CMS selectively and lastingly increased NMDA receptor subunit NR1 expression, which was reversed by ketamine or Yueju at PAD 2 but only by Yueju at PAD 6.	Ketamine	100-108	MMTV LTR integration site 2	Mus musculus	121-126